Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03697512
Title MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors International Extranodal Lymphoma Study Group (IELSG)
Age Groups: senior | adult
Covered Countries ITA | FRA | BEL

No variant requirements are available.